Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: A new approach

[1]  Y. Stern,et al.  Putting the Alzheimer’s cognitive test to the test I: Traditional psychometric methods , 2013, Alzheimer's & Dementia.

[2]  J. Hobart,et al.  Putting the Alzheimer's cognitive test to the test II: Rasch Measurement Theory , 2013, Alzheimer's & Dementia.

[3]  W. M. van der Flier,et al.  Improving the Accuracy and Precision of Cognitive Testing in Mild Dementia , 2011, Journal of the International Neuropsychological Society.

[4]  D. Andrich.  Rating scales and Rasch measurement , 2011, Expert review of pharmacoeconomics & outcomes research.

[5]  Lisa P. Barrett,et al.  Beyond the reach of traditional analyses: using Rasch to evaluate the DASH in people with multiple sclerosis , 2011, Multiple sclerosis.

[6]  Jeremy C Hobart,et al.  The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[7]  S. Zeger,et al.  The ADAS-cog's performance as a measure - lessons from the ADNI study: Part 3 - do the scale modifications add value? , 2009, Alzheimer's & Dementia.

[8]  J. Hobart,et al.  Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods. , 2009, Health technology assessment.

[9]  Jeremy C Hobart,et al.  Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations , 2007, The Lancet Neurology.

[10]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[11]  O. Almkvist,et al.  Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease , 2003, Acta neurologica Scandinavica. Supplementum.

[12]  Kathleenl N. Lohr,et al.  Assessing health status and quality-of-life instruments: Attributes and review criteria , 2002, Quality of Life Research.

[13]  P. Doraiswamy,et al.  The Alzheimer's Disease Assessment Scale: Evaluation of Psychometric Properties and Patterns of Cognitive Decline in Multicenter Clinical Trials of Mild to Moderate Alzheimer's Disease , 2001, Alzheimer disease and associated disorders.

[14]  E. Kaplan,et al.  The Boston naming test , 2001 .

[15]  R. Ihl,et al.  Alzheimer's Disease Assessment Scale: Reliability and Validity in a Multicenter Clinical Trial , 1997, International Psychogeriatrics.

[16]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[17]  P. Rubé,et al.  L’examen Clinique en Psychologie , 1959 .

[18]  J. Inglis.  A paired-associate learning test for use with elderly psychiatric patients. , 1959, The Journal of mental science.

[19]  R Garside,et al.  The harmful health effects of recreational ecstasy: a systematic review of observational evidence. , 2009, Health technology assessment.

[20]  R. Petersen,et al.  Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs: Additions to the Alzheimer's Disease Assessment Scale That Broaden Its Scope , 1997, Alzheimer disease and associated disorders.

[21]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.

[22]  K. Davis,et al.  The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. , 1983, Psychopharmacology bulletin.

[23]  G. Rasch.  On General Laws and the Meaning of Measurement in Psychology , 1961 .